Sienna Biopharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2018. For the quarter, loss from operations was $21,668,000 against $11,266,000 a year ago. Net loss before taxes was $20,239,000 against $12,938,000 a year ago. Net loss was $20,239,000 or $1.00 per basic and diluted share against $12,857,000 or $6.50 per basic and diluted share a year ago. For the six months, loss from operations was $40,145,000 against $20,260,000 a year ago. Net loss before taxes was $37,342,000 against $23,093,000 a year ago. Net loss was $37,342,000 or $1.84 per basic and diluted share against $22,966,000 or $11.81 per basic and diluted share a year ago.